Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 vaccine safety and immunogenicity study of RiVax

Trial Profile

A Phase 1/2 vaccine safety and immunogenicity study of RiVax

Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Ricin vaccine (Primary)
  • Indications Ricin poisoning
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 26 Jul 2018 According to a Soligenix media release, a Phase II study has been planned to initiate in the second half of 2018 is contingent upon exercise of the final option by the US government under NIAID contract #HHSN272201400039C and/or through other funding sources.
    • 31 Jan 2018 New trial record
    • 25 Jan 2018 According to a Soligenix media release, the company expects to initiate this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top